Skip to content
lifestyle.tasteterminal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ensysce Biosciences
Ensysce Biosciences to Showcase “A New Era in Pain Therapeutics” at PAINWeek 2026 Symposium
August 21, 2026
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
August 6, 2026
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
July 14, 2026
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
June 26, 2026
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 23, 2026
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 23, 2026
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
May 23, 2026
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
April 16, 2026
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 7, 2026
1
2
Next Page
→